International Components Corporation (ICC), an established global leader in designing and manufacturing portable rechargeable systems, today launched a new series of high-efficiency AC-DC open-frame, single output power supplies marketed under the Elpac Power Systems(TM) brand name.
The new 40-watt series features an industry-leading converter efficiency of up to 88% offered in a compact 2" x 4" (50.8mm x 101.6 mm) frame. Expanding upon the success of the MTA040 for medical applications, the FTA040, designed for commercial applications, is the latest addition to the company's rapidly expanding portfolio of high-efficiency, high-reliability power supplies.
Delivering 40 watts of continuous output power with natural convection, the FTA040 series is ideally suited for applications where space is at a premium and there is little or no airflow. This high-reliability series meets broad international performance and safety standards including TUV, UL 60950-1, CSA, CE, and CISPR22. The FTA040 also provides a long hold-up time for reliable operation at more than 14ms at any input voltage. No minimum load is required for the unit to start up and maintain stated specifications.
The power supplies are comprehensively protected against over-voltage, over-temperature, and short circuit conditions and demonstrated mean time between failure exceeds 200,000 hours. The units operate at full power from 0 to + 50 degrees C and up to + 70 degrees C with derating. The FTA040 features a universal input range of 85 to 264 VAC enabling use in any part of the world.
The FTA040 series is competitively priced starting at $20.94 U.S. in OEM quantities of 1,000 and models are available to ship today. The power supplies are available in four single output voltages ranging from 9-24 VDC. ICC can also design a 100-percent custom solution to meet specific OEM requirements. Full warranty policy and datasheets with complete technical specifications for the FTA040 and MTA040 series can be found 24/7 at http://www.iccus.com.
Canada’s proactive policies reduce drug shortages far more effectively than the U.S.